Skip to main content
Contact Us
Subscribe
E-Edition
80°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2024
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Quidelortho Corp
(NQ:
QDEL
)
38.91
+0.67 (+1.75%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Quidelortho Corp
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
ROSEN, NATIONAL TRIAL LAWYERS, Encourages QuidelOrtho Corporation Investors to Inquire About Securities Class Action Investigation - QDEL
March 02, 2024
WHY: NEW YORK, NY - (NewMediaWire) - March 02, 2024 - Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of...
Via
TheNewswire.com
QDEL ALERT: ROSEN, A RESPECTED AND LEADING FIRM, Encourages QuidelOrtho Corporation Investors to Inquire About Securities Class Action Investigation – QDEL
February 29, 2024
From
The Rosen Law Firm PA
Via
GlobeNewswire
QDEL LOSS ALERT: ROSEN, LEADING INVESTOR COUNSEL, Encourages QuidelOrtho Corporation Investors to Inquire About Securities Class Action Investigation – QDEL
February 28, 2024
From
Rosen Law Firm
Via
Business Wire
QuidelOrtho to Participate in 45th Annual Raymond James Institutional Investor Conference
February 26, 2024
From
QuidelOrtho Corporation
Via
Business Wire
QuidelOrtho Corporation (QDEL) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
February 26, 2024
From
Bronstein, Gewirtz & Grossman, LLC
Via
Business Wire
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of QuidelOrtho Corporation (QDEL) on Behalf of Investors
February 22, 2024
From
Glancy Prongay & Murray LLP
Via
Business Wire
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of QuidelOrtho Corporation (QDEL) on Behalf of Investors
February 21, 2024
From
Law Offices of Howard G. Smith
Via
Business Wire
The Law Offices of Frank R. Cruz Announces Investigation of QuidelOrtho Corporation (QDEL) on Behalf of Investors
February 21, 2024
From
Law Offices of Frank R. Cruz
Via
Business Wire
QuidelOrtho CEO Terminated: Johnson Fistel Continues Investigation
February 21, 2024
From
Johnson Fistel, LLP
Via
Business Wire
QuidelOrtho Announces Changes in Executive Leadership
February 21, 2024
From
QuidelOrtho Corporation
Via
Business Wire
Berman Tabacco Announces Investigation of QuidelOrtho Corporation (QDEL) for Potential Securities Law Violations
February 14, 2024
From
Berman Tabacco
Via
GlobeNewswire
QuidelOrtho Reports Fourth Quarter and Full-Year 2023 Financial Results
February 13, 2024
From
QuidelOrtho Corporation
Via
Business Wire
QuidelOrtho to Report Fourth Quarter and Full-year 2023 Financial Results
January 23, 2024
From
QuidelOrtho Corporation
Via
Business Wire
QuidelOrtho to Present at 42nd Annual J.P. Morgan Healthcare Conference
December 22, 2023
From
QuidelOrtho Corporation
Via
Business Wire
QuidelOrtho Receives 510(K) Clearance for Savanna® Multiplex Molecular Platform and Savanna® HSV 1+2/VZV PCR Assay
December 20, 2023
From
QuidelOrtho Corporation
Via
Business Wire
QuidelOrtho to Participate in the Evercore ISI Conference
November 16, 2023
From
QuidelOrtho Corporation
Via
Business Wire
QuidelOrtho Reports Third Quarter 2023 Financial Results
November 01, 2023
From
QuidelOrtho Corporation
Via
Business Wire
QuidelOrtho Reports Preliminary Revenue Results for the Third Quarter 2023
October 12, 2023
From
QuidelOrtho Corporation
Via
Business Wire
QuidelOrtho Receives CLIA Waiver for Sofia® 2 SARS Antigen+ FIA
September 21, 2023
From
QuidelOrtho Corporation
Via
Business Wire
QuidelOrtho to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference
August 28, 2023
From
QuidelOrtho Corporation
Via
Business Wire
QuidelOrtho Reports Second Quarter 2023 Financial Results
August 08, 2023
From
QuidelOrtho Corporation
Via
Business Wire
QuidelOrtho Ranks No. 1 in Customer Satisfaction for Six Years in a Row
July 25, 2023
From
QuidelOrtho Corporation
Via
Business Wire
QuidelOrtho Partners With BYG4lab® to Strengthen Informatics Offerings
July 25, 2023
From
QuidelOrtho Corporation
Via
Business Wire
QuidelOrtho to Report Second Quarter 2023 Financial Results
July 18, 2023
From
QuidelOrtho Corporation
Via
Business Wire
QuidelOrtho to Participate in William Blair 43rd Annual Growth Stock Conference
May 23, 2023
From
QuidelOrtho Corporation
Via
Business Wire
QuidelOrtho Reports First Quarter 2023 Financial Results
May 03, 2023
From
QuidelOrtho Corporation
Via
Business Wire
QuidelOrtho Reports Preliminary Revenue Results for the First Quarter 2023
April 13, 2023
From
QuidelOrtho Corporation
Via
Business Wire
QuidelOrtho Announces the Formation of the International QuidelOrtho Women’s Leadership Network (QWLN)
March 28, 2023
From
QuidelOrtho Corporation
Via
Business Wire
QuidelOrtho Receives De Novo FDA Authorization for Sofia® 2 SARS Antigen+ FIA
March 08, 2023
From
QuidelOrtho Corporation
Via
Business Wire
QuidelOrtho to Participate in the Raymond James 44th Annual Institutional Investor Conference
March 02, 2023
From
QuidelOrtho Corporation
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.